Castration-Resistant Prostate Cancer

P2, N=19, Completed, Dana-Farber Cancer Institute | Active, not recruiting --> Completed | Trial completion date: Apr 2026 --> Nov 2025

It exhibited potent antiproliferative effects on prostate cancer cells. These results indicate that BMX-PROTACs are potential therapeutic candidates for prostate cancer.

P1/2, N=129, Completed, Orion Corporation | Active, not recruiting --> Completed

P1/2, N=45, Not yet recruiting, AstraZeneca AB

P1, N=152, Active, not recruiting, AbbVie | Recruiting --> Active, not recruiting | N=230 --> 152

P1, N=160, Recruiting, IDEAYA Biosciences | Phase classification: P1/2 --> P1

P=N/A, N=76, Active, not recruiting, Weill Medical College of Cornell University | Trial primary completion date: Apr 2026 --> Sep 2026

In this study, testing contributivity was similar or higher that of other studies in the literature, and observed mutations prevalences were similar to that of other screenings of western populations. Harmonising per-centres protocols and enhancing molecular testing contributivity with the screening of circulating DNA samples and expanding its range by including non-BRCA HRR-related genes in all reference centres will enable more patients to be accurately treated by targeted therapies.

Notably, the therapeutic effect was comparable to that of docetaxel, a current standard-of-care chemotherapy, without noticeable side effects on body weight, proximal aorta or heart function detected in immune-deficient mice. These findings suggest that targeting TβRI cleavage using specific mAbs is a novel precision medicine approach for the treatment of mCRPC. By selectively blocking the prometastatic activity of TβRI-ICD without disrupting physiological TGFβ signaling, this strategy may provide a safer and more effective alternative to existing therapies for advanced prostate cancer.

P3, N=1524, Recruiting, Alliance for Clinical Trials in Oncology | Not yet recruiting --> Recruiting | Initiation date: Oct 2025 --> Mar 2026

The hematological parameters remained stable for the whole period of observation. The presented clinical case report describes a unique positive experience on the use of [225Ac]Ac-PSMA-617 therapy in mCRPC and brain meningioma, thus allowing us to expand our understanding of PSMA RLT as a method for the treatment of not only prostatic tumors but also tumors of non-prostatic locations.

These findings demonstrate that ATM-deficiency enhances radiobiological response and amplifies immune activation to 223Ra, supporting further pre-clinical evaluation of ATM loss as a determinant of response and therapeutic target to optimise 223Ra based strategies for mCRPC.